Skip navigation Wisconsin State Legislature
Up
CSB 2.54 History History: cr. Affirmative action order under s. 961.11 (4), Stats., Register May 2017 No. 737, eff. 5-15-17; CR 18-055: cr. Register June 2019 No. 762, eff. 7-1-19.
CSB 2.55 CSB 2.55  Addition of 5F-ADB, 5F-AMB, ADB-FUBINACA, MDMB-CHMICA and MDMB-FUBINACA to schedule I. Section 961.14 (4) (tb) 38., 39., 40., 41., and 42., Stats., is created to read:
961.14 (4) (tb) 38. Methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate, commonly known as 5F-ADB.
39. Methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3-methylbutanoate, commonly known as 5F-AMB.
40. N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide, commonly known as ADB-FUBINACA.
41. Methyl 2-(1-(cyclohexylmethyl)-1H-indole-3-carboxamido)-3,3-dimethylbutanoate commonly known as MDMB-CHMICA.
42. Methyl 2-(1-(4-fluorobenzyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate, commonly known as MDMB-FUBINACA.
CSB 2.55 History History: cr. Affirmative action order under s. 961.11 (4), Stats., Register May 2017 No. 737, eff. 5-15-17.
CSB 2.56 CSB 2.56  Addition of 4-fluoroisobutyryl fentanyl to schedule I. Section 961.14 (2) (nc), Stats., is created to read:
961.14 (2) (nc) 4-fluoroisobutyryl fentanyl (N-(4-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)isobutyramide);
CSB 2.56 History History: cr. Affirmative action order under s. 961.11 (4), Stats., Register June 2017 No. 738, eff. 6-12-17.
CSB 2.57 CSB 2.57  Scheduling of cyclopropyl fentanyl. Section 961.14 (2) (nd) 10d., Stats., is created to read:
961.14 (2) (nd) 10d. Cyclopropyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylcyclopropanecarboxamide);
CSB 2.57 History History: EmR 1716: emerg. cr. eff. 9-8-17; CR 17-0785: cr. Register July 2018 No. 751, eff. 8-1-18; corrections made under s. 35.17, Stats., Register July 2018 No. 751.
CSB 2.58 CSB 2.58  Exclusion of naldemedine. Section 961.16 (2) (a) (intro), Stats., is amended to read:
961.16 (2) (a) (intro) Opium and substances derived from opium, and any salt, compound, derivative or preparation of opium or substances derived from opium. Apomorphine, dextrorphan, nalbuphine, butorphanol, naldemedine, nalmefene, naloxegol, naloxone and naltrexone and their respective salts and the isoquinoline alkaloids of opium and their respective salts are excluded from this paragraph. The following substances, and any of their salts, isomers and salts of isomers that are theoretically possible within the specific chemical designation, are included in this paragraph:
CSB 2.58 History History: cr. Affirmative action order under s. 961.11 (4), Stats., Register November 2017 No. 743, eff. 11-20-17; CR 18-024: cr. Register June 2019 No. 762, eff. 7-1-19.
CSB 2.59 CSB 2.59  Addition of ortho-fluorofentanyl to schedule I. Section 961.14 (2) (nd) 16m., Stats., is created to read:
961.14 (2) (nd) 16m. Ortho-fluorofentanyl (N-(2-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)propionamide);
CSB 2.59 History History: cr. Affirmative action order under s. 961.11 (4), Stats., Register December 2017 No. 744, eff. 12-4-17; correction made under s. 35.17, Stats., Register December 2017 No. 744; CR 18-023: cr. Register June 2019 No. 762, eff. 7-1-19.
CSB 2.60 CSB 2.60  Addition of FUB-AMB to schedule I. Section 961.14 (4) (tb) 43., Stats., is created to read:
961.14 (4) (tb) 43. methyl 2-(1-(4-fluorobenzyl)-1H-indazole-3-carboxamido)-3-methylbutanoate, commonly known as FUB-AMB, MMB-FUBINACA or AMB-FUBINACA.
CSB 2.60 History History: cr. Affirmative action order under s. 961.11 (4), Stats., Register December 2017 No. 744, eff. 12-11-17; correction made under s. 35.17, Stats., Register December 2017 No. 744; CR 18-022: cr. Register June 2019 No. 762, eff. 7-1-19.
CSB 2.61 CSB 2.61  Addition of MT-45 to schedule I. Section 961.14 (2) (rk), Stats., is created to read:
961.14 (2) (rk) MT-45 (1-cyclohexyl-4-(1,2-diphenylethyl)piperazine);
CSB 2.61 History History: cr. Affirmative action order under s. 961.11 (4), Stats., Register January 2018 No. 745, eff. 1-22-18; correction made under s. 35.17, Stats., Register January 2018 No. 745; CR 18-069: cr. Register June 2019 No. 762, eff. 7-1-19.
CSB 2.62 CSB 2.62  Addition of para-chloroisobutyryl fentanyl to schedule I. Section 961.14 (2) (nd) 16s., Stats., is created to read:
961.14 (2) (nd) 16s. Para-chloroisobutyryl fentanyl (N-(4-chlorophenyl)-N-(1-phenethylpiperidin-4-yl)isobutyramide);
CSB 2.62 History History: cr. Affirmative action order under s. 961.11 (4), Stats., Register March 2018 No. 747, eff. 3-12-18; CR 18-070: cr. Register June 2019 No. 762, eff. 7-1-19.
CSB 2.63 CSB 2.63  Addition of NM2201, 5F-AB-PINACA, 4-CN-CUMYL-BUTINACA, MMB-CHMICA and 5F-CUMYL-P7AICA to schedule I. Section 961.14 (4) (tb) 44., 45., 46., 47., and 48., Stats., are created to read:
961.14 (4) (tb) 44. Naphthalen-1-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate, commonly known as NM2201.
45. N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide, commonly known as 5F-AM-PINACA.
46. 1-(4-cyanobutyl)-N-(2-phenylpropan-2-yl)-1H-indazole-3-carboxamide, commonly known as 4-CN-CUMYL-BUTINACA.
47. Methyl 2-(1-(cyclohexylmethyl)-1H-indole-3-carboxamido)-3-methylbutanoate, commonly known as MMB-CHMICA.
48. 1-(5-fluoropentyl)-N-(2-phenylpropan-2-yl)-1H-pyrrolo[2,3-b]pyridine-3-carboxamide, commonly known as 5F-CUMYL-P7AICA.
CSB 2.63 History History: cr. Affirmative action order under s. 961.11 (4), Stats., Register March 2018 No. 747, eff. 3-12-18; cr. Affirmative action order under s. 961.11 (4), Stats., Register August 2018 No. 752, eff. 8-13-18; correction made under s. 35.17, Stats., Register August 2018 No. 752.
CSB 2.64 CSB 2.64  Addition of N-Ethylpentylone to schedule I. Section 961.14 (7) (L) 34., Stats., is created to read:
961.14 (7) (L) 34. N-Ethylpentylone, commonly known as ephylone.
CSB 2.64 History History: cr. Affirmative action order under s. 961.11 (4), Stats., Register October 2018 No. 754, eff. 10-1-18.
CSB 2.65 CSB 2.65  Addition of approved cannabidiol drugs to schedule V. Section 961.22 (7), Stats., is created to read:
961.22 (7) Approved cannabidiol drugs. A drug product in finished dosage formulation that has been approved by the United States food and drug administration that contains cannabidiol (2-[1R-3-methyl-6R-(1-methylethenyl)-2-cyclohexen-1-yl]-5-pentyl-1,3-benzenediol) derived from cannabis and no more than 0.1 percent (w/w) residual tetrahydrocannabinols.
CSB 2.65 History History: cr. Affirmative action order under s. 961.11 (4g), Stats., Register October 2018 No. 754, eff. 10-15-18.
CSB 2.66 CSB 2.66  Addition of 5F-EDMB-PINACA, 5F-MDMB-PICA, FUB-AKB48, 5F-CUMYL-PINACA, and FUB-144 to schedule I. Section 961.14 (4) (tb), 49., 50., 51., and 52., Stats., is created to read:
961.14 (4) (tb) 49. Thyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate, commonly known as 5F-EDMB-PINACA.
50. Methyl 2-(1-(5-fluoropentyl)-1-indole-3-carboxamido)-3,3-dimethylbutanoate, commonly known as 5F-MDMB-PICA.
51. N-(adamantan-1-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide, commonly known as FUB-AKB48, FUB-APINACA or AKB48 N-(4-FLUOROBENZYL).
52. 1-(5-fluoropentyl)-N-(2-phenylpropan-2-yl)-1H-indazole-3-carboxamide, commonly known as 5F-CUMYL-PINACA or SGT-25.
53. (1-(4-fluorobenzyl)-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone, commonly known as FUB-144.
CSB 2.66 History History: cr. Affirmative action order under s. 961.11 (4), Stats., Register March 2019 No. 759, eff. 3-11-19.
CSB 2.67 CSB 2.67  Addition of Brexanolone and Solriamfetol to schedule IV. Section 961.20 (2) (p) and (2m) (g), Stats., are created to read:
961.20 (2) (ap) Brexanolone.
(2m) (g) Solriamfetol.
CSB 2.67 History History: cr. Affirmative action order under s. 961.11 (4), Stats., Register July 2019 No. 763, eff. 7-22-19.
CSB 2.68 CSB 2.68  Addition of N-Ethylhexedrone, a-PHP, 4-MEAP, MPHP, PV8 and 4-chloro-a-PVP to schedule I. Section 961.14 (7) (L) 35. to 40., Stats., is created to read:
961.14 (7) (L) 35. N-Ethylhexedrone.
36. Alpha-pyrrolidinohexanophenone, commonly known as a-PHP.
37. 4-methyl-alpha-ethylainopentiophenone, commonly known as 4-MEAP.
38. 4'-methyl-alpha-pyrrolidinohexiophenone, commonly known as MPHP.
39. Alpha-pyrrolidinoheptaphenone, commonly known as PV8.
40. 4'-chloro-alpha-pyrrolidinovalerophenone, commonly known as 4-chloro-a-PVP.
CSB 2.68 History History: cr. Affirmative action order under s. 961.11 (4g), Stats., Register August 2019 No. 764, eff. 8-19-19.
CSB 2.69 CSB 2.69  Addition of Noroxymorphone to schedule II. Section 961.16 (2) (a) 10m., Stats., is created to read:
961.16 (2) (a) 10m. Noroxymorphone.
CSB 2.69 History History: cr. Affirmative action order under s. 961.11 (4), Stats., Register November 2019 No. 767, eff. 11-11-19.
Down
Loading...
Loading...
Published under s. 35.93, Stats. Updated on the first day of each month. Entire code is always current. The Register date on each page is the date the chapter was last published.